Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis

Inclusion Criteria

• •The study includes patients with an initial pathological/histologic diagnosis of mandibular involvement by oral tumors (such as OSCC, osteosarcoma, and ameloblastoma), bisphosphonate- or immunomodulatory drug-induced osteonecrosis, and mandibular lesions from metastatic conditions originating from other sites including lung, breast, prostate, or kidney.
• •Age 18 years and older
• •Bisphosphonate related osteonecrosis of the mandible
• •Immunomodulatory drugs induced mandibular osteonecrosis
• •Patients presented with ameloblastoma affecting the mandible
• •Patients presented with osteosarcomas of the mandible
• •Patients presented with oral metastases related mandibular lesions that are indicated for segmental resection, common primary tumor sites include lung, breast, prostate and kidney
• •Undergoing primary curative treatment with segmental resection of the mandible ≥2 cm
• •Intention to undergo mandibular reconstruction with autologous bone using a primary (one-stage) or secondary (two-stage) approach
• •Informed consent obtained, ie:
• •* Ability to understand the content of the patient information/ICF
• •* Willingness and ability to participate in the clinical investigation according to the registry plan (RP) o Signed and dated IRB/EC approved ICF OR
• •* Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide to provide independent written informed consent